Australia's most trusted
source of pharma news
Posted 13 May 2022 AM
Swedish rare immunological disease specialist Hansa Biopharma is looking to market its first product in Australia, new pathways handed out by the TGA show.
Founded in 2007 and headquartered in Lund, Sweden, Hansa is focused on developing innovative immunomodulatory enzyme technology for rare immunoglobulin G mediated diseases.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.